# Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

> **NCT00093080** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 216 (actual)

## Conditions studied

- Leiomyosarcoma
- Liposarcoma
- Osteosarcoma
- Sarcoma, Soft Tissue
- Metastases

## Interventions

- **DRUG:** ridaforolimus

## Key facts

- **NCT ID:** NCT00093080
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2015-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00093080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00093080, "Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00093080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*